CIN No. : L24239DL2004PLC125888

AKUMS DRUGS & PHARMACEUTICALS LIMITED

Regd. Office : 304, 3rd Floor, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (INDIA)
Corporate Office : Akums House - Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I, Delhi-110083
Phone : 91-11 - 69041000 Fax : 91-11 27023256 E-mail : akumsho@akums.net ; website : www.akums.in

Ref: Akums/Exchange/2024-25/43

24th December, 24

To,
The Listing Department
National Stock Exchange of India Ltd
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E),
Mumbai – 400 051

Symbol: AKUMS

To,
The Listing Department
BSE Limited
25th Floor, New Trading Ring,
Rotunda Building, Phiroze
Jeejeebhoy Towers, Dalal Street,
Mumbai – 400 001

Scrip Code: 544222

Sub: LONG-TERM CDMO AGREEMENT WITH A LEADING GLOBAL PHARMA COMPANY FOR MANUFACTURE AND SUPPLY IN EUROPEAN MARKET

Respected Sir/Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (SEBI Regulation) we would like to inform you that Akums Drugs and Pharmaceuticals Limited (hereinafter referred to as "Akums") has entered into an agreement with one of Leading Global Pharma Company ("Company") for Manufacture and Supply of selected pharmaceutical formulations in European Market. Akums group will manufacture and supply multiple SKUs of Oral Liquid Formulation to be marketed in multiple European countries by the Company.

This is in line with Akums growth objective of expanding in European and other regulated markets. The commercial supply of these products from Akums will commence in 2027 till 2032. Akums group will also initiate European approvals of its oral liquid site which it intends to leverage to manufacture these products. The approval of the site and the product dossiers is expected to be received by 2026. Akums already has 2 of its sites (Injectable and Oral Solids) approved by European Regulators. The composite value of the agreement is approx. Euro 200 million (INR 1,760 crores approx).

Akums group, against this agreement, will receive an upfront payment for product development and site approval from European authorities. The project has been secured with an upfront payment of Euro 100 million (INR 880 crores).

Akums
CIN No. : L24239DL2004PLC125888
AKUMS DRUGS & PHARMACEUTICALS LIMITED
Regd. Office : 304, 3rd Floor, Mohan Place, L.S.C., Block-C, Saraswati Vihar, New Delhi-110034 (INDIA)
Corporate Office : Akums House - Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I, Delhi-110083
Phone : 91-11 - 69041000 Fax : 91-11 27023256 E-mail : akumsho@akums.net ; website : www.akums.in

Speaking on this development, Mr. Sanjeev Jain, Managing Director of Akums added "It gives us immense pleasure to enter in a strategic collaboration to manufacture and supply a globally renowned brand for one of the largest multinational pharma company. This opens doors for us to further expand our footprints in regulated markets and replicate the domestic CDMO success globally."

Mr. Sandeep Jain, Managing Director of Akums added "These products are currently being manufactured in Europe. Manufacturing these products in India opens further collaboration opportunities with other global pharma companies to optimize their manufacturing costs and make their supply chain robust. This association is the testimony of our manufacturing excellence and our world class R&D capabilities. With this, we will add one more dosage form in our portfolio, can be offered in European market. Akums already has European approved facility for tablets, hard gelatin capsules, sachets, ampoules, vials, eye-drops and dry powder injection."

Other details required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the SEBI Circular No. SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated 13th July 2023 are provided herein as **Annexure-A**.

This is for your kind information and record.

Thanking You

Your faithfully

For **Akums Drugs and Pharmaceuticals Limited**

Dharamvir Malik
Digitally signed by Dharamvir Malik
Date: 2024.12.24 12:24:03 +05'30'

Dharamvir Malik
Company Secretary & Compliance Officer

Encl: As above

Annexure A

Sr. No.	Particulars	Details
1	Name of the entity with whom agreement is signed	Leading Global Pharma Company
2	Area of agreement	Manufacturing and Supply.
3	Domestic/International	European Union (International)
4	Share exchange ratio	NA
5	Scope of business operation of agreement	Manufacturing and Supply of Oral liquid formulations.
6	Details of consideration paid / received in agreement	Composite value of Euro 200 million approximately. (INR 1760 crores approx.). Upfront payment of Euro 100 million (INR 880 crores), which will be received post banking regulation approval.
7	Significant Terms and Conditions of agreement	Long Term supply agreement commencing from 2027 till 2032.
8	Whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	NA
9	Size of the entity	Large Global pharma Company with over 10 billion USD in revenue.
10	Rationale and benefit expected.	Entry in the European Markets and sizeable business opportunity.